TR200103532T2 - Etansulfonil-piperadin türevleri - Google Patents

Etansulfonil-piperadin türevleri

Info

Publication number
TR200103532T2
TR200103532T2 TR2001/03532T TR200103532T TR200103532T2 TR 200103532 T2 TR200103532 T2 TR 200103532T2 TR 2001/03532 T TR2001/03532 T TR 2001/03532T TR 200103532 T TR200103532 T TR 200103532T TR 200103532 T2 TR200103532 T2 TR 200103532T2
Authority
TR
Turkey
Prior art keywords
hydrogen
neurodegeneration
acute
types
ethanesulfonyl
Prior art date
Application number
TR2001/03532T
Other languages
English (en)
Inventor
Alanine Alexander
Burner Serge
Buettelmann Bernd
Heitz Neidhart Marie-Paule
Jaeschke Georg
Pinard Emmanuel
Wyler Ren
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of TR200103532T2 publication Critical patent/TR200103532T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Mevcut bulus, R2' in hidrojen veya hidroksi'yi; R2' nin hidrojen veya metili; X' in -O- veya -CH2-' yi ifade ettigi genel formül (I) bilesikleri ve bunlarin farmasötik olarak kabul edilebilir asit eklemeli tuzlari ile ilgilidir. Bu bilesiklerin NMDA reseptörüne egilimleri oldugu ve bu nedenle terapötik belirtilerin arasinda örnegin darbe veya beyin travmasinin neden oldugu akut nörodejenerasyon türleri; Alzheimer, Parkinson, Huntington veya ALS (amiotropik lateral sikloz) gibi kronik nörodejenerasyon türleri; bakteriyel veya viral enfeksiyonlara, sizofreni, anksiyete, depresyon ve akut/kronik agri gibi hastaliklara bagli nörodejerasyon bulunan hastaliklarin tedavisinde faydali olduklari gösterilmektedir.
TR2001/03532T 1999-06-08 2000-05-31 Etansulfonil-piperadin türevleri TR200103532T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111126 1999-06-08

Publications (1)

Publication Number Publication Date
TR200103532T2 true TR200103532T2 (tr) 2002-05-21

Family

ID=8238316

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03532T TR200103532T2 (tr) 1999-06-08 2000-05-31 Etansulfonil-piperadin türevleri

Country Status (38)

Country Link
US (1) US6310213B1 (tr)
EP (1) EP1189886B1 (tr)
JP (1) JP3645856B2 (tr)
KR (1) KR100571162B1 (tr)
CN (1) CN1142141C (tr)
AR (1) AR024282A1 (tr)
AT (1) ATE315025T1 (tr)
AU (1) AU770787B2 (tr)
BR (1) BR0011419A (tr)
CA (1) CA2376091C (tr)
CO (1) CO5160328A1 (tr)
CZ (1) CZ299483B6 (tr)
DE (1) DE60025348T2 (tr)
DK (1) DK1189886T3 (tr)
EG (1) EG26101A (tr)
ES (1) ES2254183T3 (tr)
GC (1) GC0000256A (tr)
GT (1) GT200000089A (tr)
HK (1) HK1046412B (tr)
HR (1) HRP20010885B1 (tr)
HU (1) HU228591B1 (tr)
IL (2) IL146750A0 (tr)
JO (1) JO2260B1 (tr)
MA (1) MA26797A1 (tr)
MX (1) MXPA01012585A (tr)
MY (1) MY128818A (tr)
NO (1) NO320613B1 (tr)
PA (1) PA8496601A1 (tr)
PE (1) PE20010218A1 (tr)
PL (1) PL196053B1 (tr)
RS (1) RS50033B (tr)
RU (1) RU2242464C2 (tr)
SI (1) SI1189886T1 (tr)
TN (1) TNSN00125A1 (tr)
TR (1) TR200103532T2 (tr)
TW (1) TWI254043B (tr)
WO (1) WO2000075109A1 (tr)
ZA (1) ZA200109706B (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE273953T1 (de) * 2000-03-22 2004-09-15 Hoffmann La Roche Piperidin- und pirazinverbindungen zur verwendung in der behandlung von alzheimer
ES2225553T3 (es) 2000-04-20 2005-03-16 F. Hoffmann-La Roche Ag Derivados de pirrolidina y piperidina y su empleo para el tratamiento de trastornos neurodegenerativos.
US6407235B1 (en) 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
EP1332363A4 (en) * 2000-10-09 2007-08-29 Kay Double PROOF OF NEURODEGENERATIVE DISEASES
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
US20150045556A1 (en) * 2011-07-18 2015-02-12 Roland E. Dolle Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
PL352723A1 (en) 2003-09-08
TWI254043B (en) 2006-05-01
IL146750A (en) 2006-12-10
DE60025348T2 (de) 2006-08-24
WO2000075109A1 (en) 2000-12-14
PA8496601A1 (es) 2001-12-14
MA26797A1 (fr) 2004-12-20
BR0011419A (pt) 2002-02-26
NO20015920D0 (no) 2001-12-04
ZA200109706B (en) 2003-02-26
EP1189886B1 (en) 2006-01-04
RU2242464C2 (ru) 2004-12-20
HK1046412B (zh) 2004-07-09
GC0000256A (en) 2006-11-01
EP1189886A1 (en) 2002-03-27
HK1046412A1 (en) 2003-01-10
EG26101A (en) 2013-02-17
MY128818A (en) 2007-02-28
MXPA01012585A (es) 2002-04-10
AR024282A1 (es) 2002-09-25
CZ299483B6 (cs) 2008-08-13
HUP0201916A2 (en) 2002-10-28
YU86501A (sh) 2004-09-03
CO5160328A1 (es) 2002-05-30
CN1142141C (zh) 2004-03-17
ES2254183T3 (es) 2006-06-16
RS50033B (sr) 2008-11-28
TNSN00125A1 (fr) 2005-11-10
AU770787B2 (en) 2004-03-04
DE60025348D1 (de) 2006-03-30
JP3645856B2 (ja) 2005-05-11
DK1189886T3 (da) 2006-05-15
AU5218100A (en) 2000-12-28
HU228591B1 (hu) 2013-04-29
ATE315025T1 (de) 2006-02-15
HRP20010885A2 (en) 2004-02-29
IL146750A0 (en) 2002-07-25
SI1189886T1 (sl) 2006-04-30
NO320613B1 (no) 2005-12-27
NO20015920L (no) 2001-12-04
HRP20010885B1 (en) 2010-07-31
GT200000089A (es) 2001-11-29
JO2260B1 (en) 2004-10-07
JP2003501415A (ja) 2003-01-14
CA2376091C (en) 2006-03-14
US6310213B1 (en) 2001-10-30
CN1354745A (zh) 2002-06-19
CA2376091A1 (en) 2000-12-14
CZ20014349A3 (cs) 2002-05-15
KR20020008850A (ko) 2002-01-31
PL196053B1 (pl) 2007-11-30
KR100571162B1 (ko) 2006-04-17
HUP0201916A3 (en) 2003-05-28
PE20010218A1 (es) 2001-02-28

Similar Documents

Publication Publication Date Title
AP1853A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents.
JO2503B1 (en) Benzathiazole derivatives
NZ527123A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors
CY1105159T1 (el) (ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda
YU9602A (sh) Derivati 3(5)-amino-pirazola, postupak za njihovu izradu i njihova upotreba kao antitumornih agenasa
GEP20094736B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
RS74904A (en) Substituted pyridinones as modulators of p38 map kinase
MY138797A (en) Bacterial gyrase inhibitors and uses thereof
LU91761I2 (fr) Vernakalant et ses dérivés pharmaceutiquement acceptables et en particulier son sel d'hydrochlorure (BRINAVESS®)
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
BR0210028A (pt) Agentes antibacterianos
BR112021018238A2 (pt) Derivados de azolopiridina macrocíclicos como moduladores de eed e prc2
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
BR0113590A (pt) 7-oxo-piridopirimidinas
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
TR200103532T2 (tr) Etansulfonil-piperadin türevleri
BR0211265A (pt) Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor
BR0215067A (pt) Piridoquinoxalinas antivirais
BR0111915A (pt) 5-aminoalquilpirazolo[4,3-d]pirimidinas
PT1109560E (pt) Compostos uteis como inidores de aicarft
WO2001091796A8 (en) Methods, compounds and compositions for treating gout